BOCA RATON, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that Chairman, President, and CEO of First Wave BioPharma James Sapirstein’s presentation at the 2023 BIO Investor Forum will take place at 11:15 a.m. PDT on October 17, 2023 in the Franciscan B Room at the Hilton San Francisco.
In addition to the presentation, members of the First Wave BioPharma management team will conduct one-on-one meetings with registered investors at the conference, showcasing the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Details of the presentation are as follows:
| Event: | 2023 BIO Investor Forum |
| Presentation: | First Wave BioPharma Company Overview and Updates - Chairman, President, and CEO James Sapirstein |
| Date/Time: | Tuesday, October 17, 2023; 11:15 a.m. PDT |
| Location: | The Hilton San Francisco, 333 O’Farrell Street, San Francisco, CA The Franciscan B Room |
About First Wave BioPharma, Inc.
First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company is currently advancing a therapeutic development pipeline with multiple Phase 2 clinical stage programs built around three proprietary technologies – the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency; capeserod, a selective 5-HT4 receptor partial agonist which First Wave will pursue for gastrointestinal (GI) indications; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. First Wave BioPharma is headquartered in Boca Raton, Florida. For more information visit www.firstwavebio.com.
For more information:
First Wave BioPharma, Inc.
777 Yamato Road, Suite 502
Boca Raton, FL 33431
Phone: (561) 589-7020
Media contact:
Tiberend Strategic Advisors, Inc.
David Schemelia
(609) 468-9325
